Peter C. Taylor

Q: What Schools Are Affiliated With Peter C. Taylor

Peter C. Taylor is affiliated with the following schools: Imperial College London, University of Oxford, University of Manchester

Peter C. Taylor's AcademicInfluence.com Rankings

Peter C. Taylor

Philosophy

#7323

World Rank

#10517

Historical Rank

Logic

#4384

World Rank

#5667

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Peter C. Taylor's Degrees

Bachelors Biology University of Manchester
Masters Biomedical Sciences University of Oxford

Similar Degrees You Can Earn

Best Online Bachelor's in Biology 2026

Why Is Peter C. Taylor Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Peter C. Taylor's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. (2006) (666)
Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis (2017) (556)
Reduction of chemokine levels and leukocyte traffic to joints by tumor necrosis factor alpha blockade in patients with rheumatoid arthritis. (2000) (428)
Neutralizing monoclonal antibodies for treatment of COVID-19 (2021) (421)
Decrease in cellularity and expression of adhesion molecules by anti-tumor necrosis factor alpha monoclonal antibody treatment in patients with rheumatoid arthritis. (1996) (410)
Anti-TNF therapy: past, present and future. (2015) (371)
Anti-TNF biologic agents: still the therapy of choice for rheumatoid arthritis (2009) (357)
Cyclodextrin-threaded conjugated polyrotaxanes as insulated molecular wires with reduced interstrand interactions (2002) (348)
Comparison of ultrasonographic assessment of synovitis and joint vascularity with radiographic evaluation in a randomized, placebo-controlled study of infliximab therapy in early rheumatoid arthritis. (2004) (323)
Diagnosis and management of acute graft‐versus‐host disease (2012) (274)
The t(8;9)(p22;p24) is a recurrent abnormality in chronic and acute leukemia that fuses PCM1 to JAK2. (2005) (271)
Raised serum vascular endothelial growth factor levels are associated with destructive change in inflammatory arthritis. (2001) (259)
Anti-cytokine therapy for rheumatoid arthritis. (2000) (225)
Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate (2014) (223)
A structured literature review of the burden of illness and unmet needs in patients with rheumatoid arthritis: a current perspective (2016) (216)
Understanding strong two-photon absorption in pi-conjugated porphyrin dimers via double-resonance enhancement in a three-level model. (2004) (215)
Extremely strong near-IR two-photon absorption in conjugated porphyrin dimers: quantitative description with three-essential-states model. (2005) (208)
Hypoxia and angiogenesis in rheumatoid arthritis (2005) (196)
Novel Candidate Genes in Unstable Areas of Human Atherosclerotic Plaques (2006) (194)
Monoclonal anti‐TNFα Antibody as a Probe of Pathogenesis and Therapy of Rheumatoid Disease (1995) (191)
Systemic anti-tumor necrosis factor alpha therapy in rheumatoid arthritis down-regulates synovial tumor necrosis factor alpha synthesis. (2000) (185)
Filgotinib (GLPG0634/GS-6034), an oral JAK1 selective inhibitor, is effective in combination with methotrexate (MTX) in patients with active rheumatoid arthritis and insufficient response to MTX: results from a randomised, dose-finding study (DARWIN 1) (2016) (182)
Intravenous administration of expanded allogeneic adipose-derived mesenchymal stem cells in refractory rheumatoid arthritis (Cx611): results of a multicentre, dose escalation, randomised, single-blind, placebo-controlled phase Ib/IIa clinical trial (2016) (178)
Molecular Portraits of Early Rheumatoid Arthritis Identify Clinical and Treatment Response Phenotypes (2019) (173)
Development of a Multi-Biomarker Disease Activity Test for Rheumatoid Arthritis (2013) (171)
A Systematic Review of Serum Biomarkers Anti-Cyclic Citrullinated Peptide and Rheumatoid Factor as Tests for Rheumatoid Arthritis (2011) (161)
Synovial cellular and molecular signatures stratify clinical response to csDMARD therapy and predict radiographic progression in early rheumatoid arthritis patients (2019) (154)
Pharmacology of TNF blockade in rheumatoid arthritis and other chronic inflammatory diseases. (2010) (149)
Ultrasound-guided synovial biopsy: a safe, well-tolerated and reliable technique for obtaining high-quality synovial tissue from both large and small joints in early arthritis patients. (2015) (148)
Diagnosis and management of chronic graft‐versus‐host disease (2012) (143)
Patient Perceptions concerning Pain Management in the Treatment of Rheumatoid Arthritis (2010) (143)
Incomplete response of inflammatory arthritis to TNFα blockade is associated with the Th17 pathway (2012) (142)
Comparison of baricitinib, upadacitinib, and tofacitinib mediated regulation of cytokine signaling in human leukocyte subpopulations (2019) (141)
Pro-inflammatory activation of primary microglia and macrophages increases 18 kDa translocator protein expression in rodents but not humans (2017) (132)
Golimumab, a new human anti-tumor necrosis factor alpha antibody, administered intravenously in patients with active rheumatoid arthritis: Forty-eight-week efficacy and safety results of a phase III randomized, double-blind, placebo-controlled study. (2010) (130)
Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in ankylosing spondylitis (2012) (129)
Metabolic Profiling Predicts Response to Anti–Tumor Necrosis Factor α Therapy in Patients With Rheumatoid Arthritis (2013) (127)
VEGF and imaging of vessels in rheumatoid arthritis (2002) (124)
Synthesis of conjugated polyrotaxanes. (2003) (120)
Anti-TNF alpha therapy is useful in rheumatoid arthritis and Crohn's disease: analysis of the mechanism of action predicts utility in other diseases. (1998) (120)
Cardiovascular Safety During Treatment With Baricitinib in Rheumatoid Arthritis (2019) (116)
Ofatumumab, a fully human anti-CD20 monoclonal antibody, in biological-naive, rheumatoid arthritis patients with an inadequate response to methotrexate: a randomised, double-blind, placebo-controlled clinical trial (2011) (115)
Clinical efficacy of launched JAK inhibitors in rheumatoid arthritis (2019) (115)
CONJUGATED PORPHYRIN OLIGOMERS FROM MONOMER TO HEXAMER (1998) (107)
Synovial hypoxia as a cause of tendon rupture in rheumatoid arthritis. (2008) (107)
Ultrasonographic and radiographic results from a two-year controlled trial of immediate or one-year-delayed addition of infliximab to ongoing methotrexate therapy in patients with erosive early rheumatoid arthritis. (2006) (101)
Enhanced Electronic Conjugation in Anthracene-Linked Porphyrins. (1998) (101)
Mesenchymal cells expressing bone morphogenetic protein receptors are present in the rheumatoid arthritis joint. (2000) (101)
The role of extracorporeal photopheresis in the management of cutaneous T‐cell lymphoma, graft‐versus‐host disease and organ transplant rejection: a consensus statement update from the UK Photopheresis Society (2017) (99)
Anti-TNF therapy: where have we got to in 2005? (2005) (99)
Antibody therapy for rheumatoid arthritis. (2003) (98)
Tumour necrosis factor inhibition versus rituximab for patients with rheumatoid arthritis who require biological treatment (ORBIT): an open-label, randomised controlled, non-inferiority, trial (2016) (90)
Call for action: how to improve use of patient-reported outcomes to guide clinical decision making in rheumatoid arthritis (2018) (87)
Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial (2021) (87)
Extracorporeal photopheresis: a focus on apoptosis and cytokines. (2006) (85)
Dramatic enhancement of intrinsic two-photon absorption in a conjugated porphyrin dimer (2004) (85)
Biological Therapies in Immune-Mediated Inflammatory Diseases: Can Biosimilars Reduce Access Inequities? (2019) (84)
Anti-TNFalpha therapy for rheumatoid arthritis: an update. (2003) (83)
Anti-tumour necrosis factor specific antibody (infliximab) treatment provides insights into the pathophysiology of rheumatoid arthritis (1999) (81)
Immunotherapy for rheumatoid arthritis. (2001) (81)
Serum vascular markers and vascular imaging in assessment of rheumatoid arthritis disease activity and response to therapy. (2005) (80)
Molecular therapeutic targets in rheumatoid arthritis (2005) (77)
Shedding of lymphocyte function-associated antigen-1 (LFA-1) in a human inflammatory response. (2006) (76)
Patient-reported outcomes from a phase 3 study of baricitinib versus placebo or adalimumab in rheumatoid arthritis: secondary analyses from the RA-BEAM study (2017) (74)
Contemporary treatment principles for early rheumatoid arthritis: a consensus statement. (2009) (73)
Excitonic Interactions in the Singlet and Triplet Excited States of Covalently Linked Zinc Porphyrin Dimers (2000) (67)
Arthritis prevention in the pre-clinical phase of RA with abatacept (the APIPPRA study): a multi-centre, randomised, double-blind, parallel-group, placebo-controlled clinical trial protocol (2018) (64)
Tumour necrosis factor alpha as a therapeutic target for immune-mediated inflammatory diseases. (2004) (62)
Physical function improvements and relief from fatigue and pain are associated with increased productivity at work and at home in rheumatoid arthritis patients treated with certolizumab pegol (2010) (61)
Safety and Efficacy of Baricitinib Through 128 Weeks in an Open-label, Longterm Extension Study in Patients with Rheumatoid Arthritis (2018) (61)
Synovial tissue signatures enhance clinical classification and prognostic/treatment response algorithms in early inflammatory arthritis and predict requirement for subsequent biological therapy: results from the pathobiology of early arthritis cohort (PEAC) (2019) (61)
Patient's global assessment of disease activity and patient's assessment of general health for rheumatoid arthritis activity assessment: are they equivalent? (2012) (61)
The value of sensitive imaging modalities in rheumatoid arthritis (2003) (60)
Cytokine blockade in rheumatoid arthritis. (2001) (60)
Anti-cytokines and cytokines in the treatment of rheumatoid arthritis. (2003) (57)
The macrophage marker translocator protein (TSPO) is down-regulated on pro-inflammatory ‘M1’ human macrophages (2017) (56)
Effect of statins on proteolytic activity in the wall of abdominal aortic aneurysms (2008) (56)
Benzofuran trimers for organic electroluminescence. (2004) (56)
Monoclonal antibodies in immune and inflammatory diseases. (2002) (55)
Raised circulating tenascin-C in rheumatoid arthritis (2012) (54)
Anti-TNFalpha therapy of rheumatoid arthritis: what can we learn about chronic disease? (2004) (52)
Patient Expectations and Perceptions of Goal-setting Strategies for Disease Management in Rheumatoid Arthritis (2015) (51)
Abatacept with methotrexate versus other biologic agents in treatment of patients with active rheumatoid arthritis despite methotrexate: a network meta-analysis (2011) (50)
How to Get the Most from Methotrexate (MTX) Treatment for Your Rheumatoid Arthritis Patient?—MTX in the Treat-to-Target Strategy (2019) (48)
The Jak/STAT pathway: A focus on pain in rheumatoid arthritis. (2020) (47)
Towards understanding the phenotypes of myocardial involvement in the presence of self-limiting and sustained systemic inflammation: a magnetic resonance imaging study (2009) (44)
OSKIRA-4: a phase IIb randomised, placebo-controlled study of the efficacy and safety of fostamatinib monotherapy (2013) (44)
Photoexcitations of Covalently Bridged Zinc Porphyrin Oligomers: Frenkel versus Wannier−Mott Type Excitons (2001) (44)
Effects of Baricitinib on Lipid, Apolipoprotein, and Lipoprotein Particle Profiles in a Phase IIb Study of Patients With Active Rheumatoid Arthritis (2017) (43)
Circulating B-cell activating factor level predicts clinical response of chronic graft-versus-host disease to extracorporeal photopheresis. (2011) (42)
Achieving Pain Control in Rheumatoid Arthritis with Baricitinib or Adalimumab Plus Methotrexate: Results from the RA-BEAM Trial (2019) (41)
Coupling Vascular and Myocardial Inflammatory Injury into a Common Phenotype of Cardiovascular Dysfunction: Systemic Inflammation and Aging – A Mini-Review (2010) (40)
Anti-inflammatory treatment improves high-density lipoprotein function in rheumatoid arthritis (2016) (40)
The IL-20 Cytokine Family in Rheumatoid Arthritis and Spondyloarthritis (2018) (40)
Translocator Protein as an Imaging Marker of Macrophage and Stromal Activation in Rheumatoid Arthritis Pannus (2018) (40)
Hindered fluorescence quenching in an insulated molecular wire. (2003) (39)
Lipid profile and effect of statin treatment in pooled phase II and phase III baricitinib studies (2018) (37)
Baricitinib Versus Placebo or Adalimumab in Patients with Active Rheumatoid Arthritis (RA) and an Inadequate Response to Background Methotrexate Therapy: Results of a Phase 3 Study (2015) (37)
Filgotinib for the treatment of rheumatoid arthritis (2017) (37)
Anti‐tumour necrosis factor treatment increases circulating T helper type 17 cells similarly in different types of inflammatory arthritis (2015) (37)
OX40L blockade is therapeutic in arthritis, despite promoting osteoclastogenesis (2014) (35)
Anti-Tumour Necrosis Factor Therapy for Dupuytren's Disease: A Randomised Dose Response Proof of Concept Phase 2a Clinical Trial (2018) (35)
Reproducibility of sodium MRI measures of articular cartilage of the knee in osteoarthritis. (2012) (34)
Increase in circulating Th17 cells during anti-TNF therapy is associated with ultrasonographic improvement of synovitis in rheumatoid arthritis (2016) (34)
Quantitative Power Doppler Ultrasonography Is a Sensitive Measure of Metacarpophalangeal Joint Synovial Vascularity in Rheumatoid Arthritis and Declines Significantly Following a 2-week Course of Oral Low-dose Corticosteroids (2010) (34)
Biological insights from clinical trials with anti-TNF therapy (2004) (33)
Degenerate four-wave mixing studies of butadiyne-linked conjugated porphyrin oligomers (1999) (33)
Rituximab versus tocilizumab in rheumatoid arthritis: synovial biopsy-based biomarker analysis of the phase 4 R4RA randomized trial (2022) (33)
B Cell Synovitis and Clinical Phenotypes in Rheumatoid Arthritis: Relationship to Disease Stages and Drug Exposure (2019) (33)
Synovial synthesis of rheumatoid factors and immune complex constituents in early arthritis. (1984) (33)
Quantitative power Doppler ultrasound measures of peripheral joint synovitis in poor prognosis early rheumatoid arthritis predict radiographic progression. (2016) (32)
Role of Biological Agents in Treatment of Rheumatoid Arthritis. (2019) (32)
Effect of Baricitinib and Adalimumab in Reducing Pain and Improving Function in Patients with Rheumatoid Arthritis in Low Disease Activity: Exploratory Analyses from RA-BEAM (2019) (31)
RORγt inhibitors suppress T(H)17 responses in inflammatory arthritis and inflammatory bowel disease. (2016) (30)
Indirect Treatment Comparison of Abatacept with Methotrexate Versus Other Biologic Agents for Active Rheumatoid Arthritis Despite Methotrexate Therapy in the United Kingdom (2012) (30)
Faculty Opinions recommendation of The effect of anti-tumour necrosis factor alpha treatment on the antibody response to influenza vaccination. (2008) (29)
Safety of baricitinib for the treatment of rheumatoid arthritis over a median of 4.6 and up to 9.3 years of treatment: final results from long-term extension study and integrated database (2021) (29)
Ultrasonographic measures of synovitis in an early phase clinical trial: a double-blind, randomised, placebo and comparator controlled phase IIa trial of GW274150 (a selective inducible nitric oxide synthase inhibitor) in rheumatoid arthritis. (2012) (29)
Extracorporeal Photopheresis Normalizes Some Lymphocyte Subsets (Including T Regulatory Cells) in Chronic Graft‐Versus‐Host‐Disease (2008) (28)
Patient-reported outcomes and safety in patients undergoing synovial biopsy: comparison of ultrasound-guided needle biopsy, ultrasound-guided portal and forceps and arthroscopic-guided synovial biopsy techniques in five centres across Europe (2018) (28)
Is a Recurrent Abnormality in Chronic and Acute Leukemia that Fuses PCM 1 to JAK 2 (2005) (28)
Use of daily electronic patient-reported outcome (PRO) diaries in randomized controlled trials for rheumatoid arthritis: rationale and implementation (2019) (28)
Anti-tumor necrosis factor alpha therapy of rheumatoid arthritis. Mechanism of action. (1997) (27)
A comparative study into the mechanisms of action of anti-tumor necrosis factor alpha, anti-CD4, and combined anti-tumor necrosis factor alpha/anti-CD4 treatment in early collagen-induced arthritis. (2000) (27)
T1-Weighted Sodium MRI of the Articulator Cartilage in Osteoarthritis: A Cross Sectional and Longitudinal Study (2013) (25)
The biology of IL-23 and IL-17 and their therapeutic targeting in rheumatic diseases (2015) (25)
Efficacy and safety of bimekizumab as add-on therapy for rheumatoid arthritis in patients with inadequate response to certolizumab pegol: a proof-of-concept study (2019) (24)
Lymphocytes Treated by Extracorporeal Photopheresis Demonstrate a Drop in the Bcl-2/Bax Ratio: A Possible Mechanism Involved in Extracorporeal-Photopheresis-Induced Apoptosis (2002) (24)
Characterization and Changes of Lymphocyte Subsets in Baricitinib‐Treated Patients With Rheumatoid Arthritis (2018) (23)
Plasma Levels of Eicosapentaenoic Acid Are Associated with Anti-TNF Responsiveness in Rheumatoid Arthritis and Inhibit the Etanercept-driven Rise in Th17 Cell Differentiation in Vitro (2017) (22)
Regulatory T Cells in Chronic Graft-Versus-Host Disease After Extracorporeal Photopheresis: Correlation With Skin and Global Organ Responses, and Ability to Taper Steroids (2017) (22)
Efficacy of IL-6 receptor antagonist Mra in rheumatoid arthritis patients with an incomplete response to methotrexate (CHARISMA). (2003) (22)
The impact of theoretical errors on velocity estimation and accuracy of duplex grading of carotid stenosis. (2002) (22)
Clinical characteristics and patient-reported outcomes in patients with inadequately controlled rheumatoid arthritis despite ongoing treatment (2018) (21)
Advances in positron emission tomography for the imaging of rheumatoid arthritis (2017) (21)
Efficacy and safety of monotherapy with sirukumab compared with adalimumab monotherapy in biologic-naïve patients with active rheumatoid arthritis (SIRROUND-H): a randomised, double-blind, parallel-group, multinational, 52-week, phase 3 study (2018) (21)
Ultrasound of metacarpophalangeal joints is a sensitive and reliable endpoint for drug therapies in rheumatoid arthritis: results of a randomized, two-center placebo-controlled study (2012) (21)
Comparative effectiveness of improvement in pain and physical function for baricitinib versus adalimumab, tocilizumab and tofacitinib monotherapies in rheumatoid arthritis patients who are naïve to treatment with biologic or conventional synthetic disease-modifying antirheumatic drugs: a matching-ad (2020) (21)
Repeatability and response to therapy of dynamic contrast-enhanced magnetic resonance imaging biomarkers in rheumatoid arthritis in a large multicentre trial setting (2017) (20)
Editorial: Combination Cytokine Blockade: The Way Forward in Therapy for Rheumatoid Arthritis? (2015) (19)
Adopting PROs in virtual and outpatient management of RA (2020) (19)
Erythrocyte autoantibodies , autoimmune haemolysis , and myelodysplastic syndromes (19)
Impact of Comorbidity (2017) (18)
The RA-MAP Consortium: a working model for academia–industry collaboration (2018) (18)
Extracorporeal photopheresis reduces the number of mononuclear cells that produce pro‐inflammatory cytokines, when tested ex‐vivo (2002) (18)
A randomized, placebo-controlled experimental medicine study of RIPK1 inhibitor GSK2982772 in patients with moderate to severe rheumatoid arthritis (2021) (18)
Filgotinib, a JAK1 Inhibitor, Modulates Disease-Related Biomarkers in Rheumatoid Arthritis: Results from Two Randomized, Controlled Phase 2b Trials (2020) (18)
Safety of Repeated Open-Label Treatment Courses of Intravenous Ofatumumab, a Human Anti-CD20 Monoclonal Antibody, in Rheumatoid Arthritis: Results from Three Clinical Trials (2016) (18)
The Clinical Features, Pathogenesis and Methotrexate Therapy of Chronic Chikungunya Arthritis (2019) (18)
24-Week Results of a Blinded Phase 2b Dose-Ranging Study of Baricitinib, an Oral Janus Kinase 1/Januse Kinase 2 Inhibitor, in Combination with Traditional Disease Modifying Antirheumatic Drugs in Patients with Rheumatoid Arthritis. (2012) (17)
The importance of the patients' experience of RA compared with clinical measures of disease activity. (2010) (17)
Clinical outcomes in patients switched from adalimumab to baricitinib due to non-response and/or study design: phase III data in patients with rheumatoid arthritis (2019) (17)
The Development of Complex Digital Health Solutions: Formative Evaluation Combining Different Methodologies (2018) (17)
Systematic Literature Review of Residual Symptoms and an Unmet Need in Patients With Rheumatoid Arthritis (2020) (17)
Evaluating automated dynamic contrast enhanced wrist 3T MRI in healthy volunteers: one-year longitudinal observational study. (2013) (17)
Treatment Mode Preferences in Rheumatoid Arthritis: Moving Toward Shared Decision-Making (2020) (16)
TNFα regulates cortisol metabolism in vivo in patients with inflammatory arthritis (2014) (16)
Treatment Satisfaction, Patient Preferences, and the Impact of Suboptimal Disease Control in a Large International Rheumatoid Arthritis Cohort: SENSE Study (2021) (16)
Effects of treatment of rheumatoid arthritis patients with an antibody against tumour necrosis factor alpha on reticuloendothelial and intrapulmonary granulocyte traffic. (1999) (16)
Early reduction in number of T cells producing proinflammatory cytokines, observed after extracorporeal photopheresis, is not linked to apoptosis induction. (2003) (16)
Developing anti-TNF and biologic agents. (2011) (16)
The Key Comorbidities in Patients with Rheumatoid Arthritis: A Narrative Review (2021) (16)
Anti-TNF alpha therapy in rheumatoid arthritis--current and future directions. (2000) (15)
Confinement Effects and Charge Dynamics in Zn3N2 Colloidal Quantum Dots: Implications for QD-LED Displays (2019) (15)
Study protocol: A multi-centre, double blind, randomised, placebo-controlled, parallel group, phase II trial (RIDD) to determine the efficacy of intra-nodular injection of anti-TNF to control disease progression in early Dupuytren's disease, with an embedded dose response study. (2017) (15)
TLR expression profiles are a function of disease status in rheumatoid arthritis and experimental arthritis. (2021) (15)
Prevalence of subjective voice impairment in rheumatoid arthritis (2008) (15)
Treatment of cutaneous T cell lymphoma with extracorporeal photopheresis induces Fas-ligand expression on treated T cells, but does not suppress the expression of co-stimulatory molecules on monocytes. (2003) (14)
Spondyloarthropathy: interleukin 23 and disease modification (2015) (14)
The ethics of ‘Trials within Cohorts’ (TwiCs): 2nd international symposium (2017) (14)
An objective method for grading ultrasound images of carotid artery plaques. (2001) (13)
A1.72 Baricitinib, an oral janus kinase inhibitor, in the treatment of rheumatoid arthritis: safety and efficacy in an open-label, long-term extension study1 (2013) (13)
Maintenance of Efficacy and Safety with Subcutaneous Golimumab Among Patients with Active Rheumatoid Arthritis Who Previously Received Intravenous Golimumab (2011) (13)
Contrast enhancement imaging in coronary arteries in SLE. (2012) (13)
VEGF release is associated with hypoxia in inflammatory arthritis(.) (2000) (12)
Novel biomarkers of a peripheral blood interferon signature associated with drug-naïve early arthritis patients distinguish persistent from self-limiting disease course (2020) (11)
Rheumatoid arthritis: pathogenic mechanisms and therapeutic targets (2004) (11)
Update on the diagnosis and management of early rheumatoid arthritis. (2020) (11)
Magnetic Resonance Imaging Substudy in a Phase 2b Dose-Ranging Study of Baricitinib, an Oral Janus Kinase 1/Janus Kinase 2 Inhibitor, in Combination with Traditional Disease-Modifying Antirheumatic Drugs in Patients with Rheumatoid Arthritis. (2012) (11)
Variation in the use of biologics in the management of rheumatoid arthritis across the UK (2012) (10)
Reduction in cellularity and expression of adhesion molecules in rheumatoid synovial tissue after anti-TNFα monoclonal antibody treatment. (1996) (10)
Reduced synovial vascularity following TNF alpha blockade in rheumatoid arthritis. (1998) (10)
A7.16 Characterisation of changes in lymphocyte subsets in baricitinib-treated patients with rheumatoid arthritis in two phase 3 studies (2016) (9)
Study protocol: A multi-centre, double blind, randomised, placebo-controlled, parallel group, phase II trial (RIDD) to determine the efficacy of intra-nodular injection of anti-TNF to control disease progression in early Dupuytren’s disease, with an embedded dose response study. (2017) (9)
Efficacy of baricitinib in patients with moderate-to-severe rheumatoid arthritis with 3 years of treatment: results from a long-term study (2020) (9)
Decrease in articular hypoxia and synovial blood flow at early time points following infliximab and etanercept treatment in rheumatoid arthritis. (2016) (9)
Added value of combining methotrexate with a biological agent compared to biological monotherapy in rheumatoid arthritis patients: A systematic review and meta-analysis of randomised trials. (2019) (9)
Call for action: incorporating wellness practices into a holistic management plan for rheumatoid arthritis—going beyond treat to target (2021) (9)
Extracorporeal Photopheresis Differentially Regulates the Expression of Phosphorylated STAT-1 and STAT-5 in Treated Monocytes and T cells, Respectively (2004) (9)
How do the efficacy and safety of abatacept and infliximab compare in the treatment of active RA? (2009) (8)
Temporal summation of pain and ultrasound Doppler activity as predictors of treatment response in patients with rheumatoid arthritis: protocol for the Frederiksberg hospitals Rheumatoid Arthritis, pain assessment and Medical Evaluation (FRAME-cohort) study (2014) (8)
The Mismeasure of Risk (2010) (8)
Comparison of the CELLEX™ and UVAR‐XTS™ closed‐system extracorporeal photopheresis devices in the treatment of chronic graft‐versus‐host disease (2017) (8)
Most Trial Eligibility Criteria and Patient Baseline Characteristics Do Not Modify Treatment Effect in Trials Using Targeted Therapies for Rheumatoid Arthritis: A Meta-Epidemiological Study (2015) (7)
Efficacy and Safety of Monotherapy with Sirukumab, an Anti-IL-6 Cytokine Monoclonal Antibody, Compared with Adalimumab Monotherapy in Biologic-Naive Patients with Active Rheumatoid Arthritis: Results of a Global, Randomized, Double-Blind, Parallel-Group, Phase 3 Study (2016) (7)
Early Metacarpal Bone Mineral Density Loss Using Digital X-Ray Radiogrammetry and 3-Tesla Wrist MRI in Established Rheumatoid Arthritis: A Longitudinal One-Year Observational Study (2015) (7)
Atypical presentation of Crohn's disease: severe, recurrent iron deficiency anemia dependent on blood transfusions. (1994) (7)
New approaches to therapeutic immunomodulation for immune-mediated inflammatory disorders. (2004) (7)
Combined power color Doppler and greyscale ultrasound demonstrate an association between vascularity and erosions in rheumatoid arthritis. (2000) (7)
A Review of Safety Outcomes from Clinical Trials of Baricitinib in Rheumatology, Dermatology and COVID-19 (2022) (7)
12-and 24-Week Patient-Reported Outcomes From a Phase 2b Dose-Ranging Study of Baricitinib, an Oral Janus Kinase 1/Janus Kinase 2 Inhibitor, in Combination with Traditional Disease-Modifying Antirheumatic Drugs in Patients with Rheumatoid Arthritis (2012) (7)
Protocol for evaluating and implementing a pragmatic value-based healthcare management model for patients with inflammatory arthritis: a Danish population-based regional cohort and qualitative implementation study (2018) (7)
A Phase III Randomized Study of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, for Active Ankylosing Spondylitis (2021) (6)
Ultrasound imaging in spondyloathropathies: from imaging to diagnostic intervention (2008) (6)
When the first visit to the rheumatologist is established rheumatoid arthritis. (2019) (6)
Current status review: the severe combined immunodeficient (SCID) mouse: xenogeneic-SCID chimeras in the investigation of human autoimmune disease. (1992) (6)
Phase IB/Iia Study On Intravenous Administration Of Expanded Allogeneic Adipose-Derived Mesenchymal Stem Cells In Refractory Rheumatoid Arthritis Patients (2013) (6)
Novel methodology to discern predictors of remission and patterns of disease activity over time using rheumatoid arthritis clinical trials data (2018) (6)
Aetiopathology of rheumatoid arthritis (2010) (6)
The expression of CD10 by apoptotic lymphocytes is preceded by a pronounced externalization of phosphatidylserine. (2000) (6)
The common pathways, but different outcomes, of apoptosis induced by extracorporeal photopheresis and in vivo chemotherapy may reinforce the important immunomodulatory effect of monocytes. (2002) (6)
MRI and Dose Selection in a Phase II Trial of Baricitinib with Conventional Synthetic Disease-modifying Antirheumatic Drugs in Rheumatoid Arthritis (2019) (6)
PMS42 COST-EFFECTIVENESS OF CERTOLIZUMAB PEGOL PLUS METHOTREXATE OR AS MONOTHERAPY FOR THE TREATMENT OF ACTIVE RHEUMATOID ARTHRITIS IN THE UNITED KINGDOM (2010) (5)
63 – Tumor necrosis factor–blocking therapies (2015) (5)
Communication Strategies Are Highly Important to Avoid Nocebo Effect When Performing Non-Medical Switch from Originator Product to Biosimilar Product: Danish Results from Applying the Parker Model a Qualitative 3-Step Research Model (2017) (5)
Patients with Rheumatoid Arthritis Acquire Sustainable Skills for Home Monitoring: A Prospective Dual-country Cohort Study (ELECTOR Clinical Trial I) (2019) (5)
Rituximab in the treatment of rheumatoid arthritis (2007) (5)
The future of TNF-α antagonism (2007) (5)
PREDICTING RESPONSES TO ANTI-TNF alpha THERAPY IN PATIENTS WITH RHEUMATOID ARTHRITIS USING METABOLOMIC ANALYSIS OF URINE (2012) (5)
Rheumatoid arthritis and the emergence of immuno-autonomics. (2019) (5)
Targeted literature review of current treatments and unmet need in moderate rheumatoid arthritis in the United Kingdom (2021) (5)
Characterization of disease course and remission in early seropositive rheumatoid arthritis: results from the TACERA longitudinal cohort study (2021) (4)
Synovial fluid fingerprinting in end-stage knee osteoarthritis: a novel biomarker concept to assess disease modifying therapies (2018) (4)
Cardiovascular safety - Update from up to 6 years of treatment with Baricitinib in Rheumatoid Arthritis clinical trials (2018) (4)
Treating to target or treating the patient in rheumatoid arthritis? (2019) (4)
The JAK inhibitor baricitinib inhibits oncostatin M induction of proinflammatory mediators in ex-vivo synovial derived cells. (2020) (4)
The expression of CD10 by apoptotic lymphocytes is preceded by a pronounced externalization of phosphatidylserine (2000) (4)
Infliximab attenuates joint destruction in early RA patients with ultrasonographic markers of poor prognosis. (2002) (4)
Insights into the pathogenesis of rheumatoid arthritis from application of anti-TNF therapy. (2000) (4)
Factors influencing the use of biologic therapy and adoption of treat-to-target recommendations in current European rheumatology practice (2018) (4)
Analysis of Immunogenicity Data in the Product Information of Biological Drugs: A Need to Report Immunogenicity Data Systematically (2019) (4)
PMS35 COST-EFFECTIVENESS OF BIOLOGIC THERAPEUTIC SEQUENCES FOR RHEUMATOID ARTHRITIS IN THE UK (2009) (3)
Erratum to: A Systematic Review of Serum Biomarkers Anti-Cyclic Citrullinated Peptide and Rheumatoid Factor as Tests for Rheumatoid Arthritis (2012) (3)
Oral Abstracts 1: Connective Tissue DiseaseO1. Long-Term Outcomes of Children Born to Mothers with SLE (2013) (3)
Rapid and Sustained Pain Improvement in Rheumatoid Arthritis Patients Treated with Baricitinib Compared to Adalimumab or Placebo (2017) (3)
Expectations of Treatment Goals and Goal-Setting Practices in People with Rheumatoid Arthritis (2011) (3)
Oral Abstracts 7: RA ClinicalO37. Long-Term Outcomes of Early RA Patients Initiated with Adalimumab Plus Methotrexate Compared with Methotrexate Alone Following a Targeted Treatment Approach (2013) (3)
MRI-detected bone marrow edema in early rheumatoid arthritis (2008) (3)
Corrigendum: The RA-MAP Consortium: a working model for academia–industry collaboration (2018) (3)
Achieving pain control in early rheumatoid arthritis with baricitinib monotherapy or in combination with methotrexate versus methotrexate monotherapy (2022) (3)
Hypoxia-driven angiogenesis is a key feature of tendon disease in rheumatoid arthritis (2006) (3)
Median time to pain improvement and the impact of baseline pain severity on pain response in patients with psoriatic arthritis treated with tofacitinib (2021) (3)
The Use of Scid Mice in the Investigation of Human Autoimmune Disease (1994) (3)
Photopheresis up-regulates CD36 on monocytes and reduces CD25(+) and CD28(+) T cell numbers. (2005) (3)
Disease status in human and experimental arthritis, and response to TNF blockade, is associated with MHC class II invariant chain (CD74) isoform expression. (2022) (3)
Using a novel smartphone application for capturing of patient-reported outcome measures among patients with inflammatory arthritis:A randomized, crossover, agreement study. (2021) (3)
The Parker Model: Applying a Qualitative Three-Step Approach to Optimally Utilize Input from Stakeholders When Introducing New Device Technologies in the Management of Chronic Rheumatic Diseases (2018) (3)
Pain Reduction in Rheumatoid Arthritis Patients Who Use Opioids: A Post Hoc Analysis of Phase 3 Trials of Baricitinib (2021) (3)
The Odd Couple?-Hardly. (2017) (3)
AB0838 IDENTIFYING MEDIATORS OF PAIN REDUCTION IN PATIENTS WITH PSORIATIC ARTHRITIS TREATED WITH TOFACITINIB: ROLE OF INFLAMMATION ASSOCIATED WITH PERIPHERAL ARTHRITIS, ENTHESITIS AND SKIN DISEASE (2020) (2)
THU0579 “EVOLVING THE MANAGEMENT OF RA” PROGRAMME: EDUCATIONAL TOOLS TO SUPPORT DAILY PRACTICE (2020) (2)
AB0768 BASELINE PAIN SEVERITY AS A PREDICTOR OF PAIN IMPROVEMENT FOLLOWING TREATMENT WITH TOFACITINIB IN PSORIATIC ARTHRITIS (2019) (2)
Microarray Pathway Analysis Comparing Baricitinib and Adalimumab in Moderate to Severe Rheumatoid Arthritis Patients, from a Phase 3 Study (2017) (2)
Influence of information provided prior to switching from Humira to biosimilar adalimumab on UK patients’ satisfaction: a cross-sectional survey by patient organisations (2022) (2)
Rheumatoid arthritis oral abstractsO01. Efficacy and Safety of Baricitinib Versus Placebo and Adalimumab in Patients with Moderately to Severely Active Rheumatoid Arthritis and Inadequate Response to Methotrexate: Summary Results from the 52-Week Phase 3 RA-Beam Study (2017) (2)
Synovial fluid fingerprinting in end-stage knee osteoarthritis (2020) (2)
SAT0687 EVOLVING THE MANAGEMENT OF RHEUMATOID ARTHRITIS THROUGH DEVELOPMENT OF PRACTICAL AND EDUCATIONAL TOOLS (2019) (2)
THU0081 Differences in patient-reported outcomes between baricitinib and comparators among patients with rheumatoid arthritis who achieved low disease activity or remission (2017) (2)
SAT0102 ASSOCIATION BETWEEN BASELINE HAEMOGLOBIN LEVELS AND RADIOGRAPHIC JOINT DAMAGE PROGRESSION IN PATIENTS WITH RHEUMATOID ARTHRITIS TREATED WITH BARICITINIB OR STANDARD OF CARE (2019) (2)
Pain in Rheumatoid Arthritis: Could JAK Inhibition be the Answer? (2020) (2)
Magnetic resonance imaging (MRI) of arthritic wrists - Getting around the pain barrier towards successful longitudinal imaging (2008) (2)
Rheumatoid arthritis 2 (2020) (2)
Is abatacept an effective treatment for patients with RA who do not respond to other anti-TNF treatments? (2006) (2)
Synovial synthesis ofrheumatoid factors andimmune complex constituents inearly arthritis (1984) (2)
OP0001 BARICITINIB, TOFACITINIB, UPADACITINIB, FILGOTINIB, AND CYTOKINE SIGNALING IN HUMAN LEUKOCYTE SUBPOPULATIONS: AN UPDATED EX-VIVO COMPARISON (2020) (2)
Biologic Therapies for Rheumatoid Arthritis Targeting TNF-α and IL-1 (2007) (2)
Is the Vasculature a Potential Therapeutic Target in Arthritis (2006) (2)
Correction to: Use of daily electronic patient-reported outcome (PRO) diaries in randomized controlled trials for rheumatoid arthritis: rationale and implementation (2019) (2)
Cytosine arabinoside does not cause differentiation in vitro of CFU-GM in marrow from normal, myelodysplastic or ANLL subjects. (1990) (2)
The effect of tofacitinib on residual pain in patients with rheumatoid arthritis and psoriatic arthritis (2022) (2)
THU0087 Synovial Ectopic Lymphoid-like Structures are Associated with Diagnosis of Rheumatoid Arthritis, Disease Activity and Antibody Status in Early Arthritis Patients (2013) (2)
Contrast enhancement imaging in coronary arteries in patients with systemic lupus erythematosus (2012) (2)
Photo‐ and Electroluminescence from Zn‐Doped InN Semiconductor Nanocrystals (2020) (2)
Early RA patients on infiliximab therapy show significant changes in sonographic measures of joint vascularity and serum VEGF by 18 weeks. (2001) (2)
SAT0123 TREATMENT SATISFACTION, EXPECTATIONS, PATIENT PREFERENCES AND CHARACTERISTICS, INCLUDING DIGITAL HEALTH LITERACY (DHL), AND THE IMPACT OF SUBOPTIMAL DISEASE CONTROL IN A LARGE INTERNATIONAL COHORT OF PATIENTS WITH RHEUMATOID ARTHRITIS (RA): THE SENSE STUDY (2020) (2)
Itch as Major Mediator of Effect of Tofacitinib on Health-Related Quality of Life in Psoriatic Arthritis: A Mediation Analysis (2021) (2)
Cell-Targeted Biologics and Emerging Targets: Rituximab, Abatacept, and Other Biologics (2009) (2)
Patient-reported outcome measures in systemic lupus erythematosus by a web-based application: A randomized, crossover, agreement study (2021) (1)
IL‐6 inhibition in the treatment of rheumatoid arthritis (2007) (1)
Semi-automating bone segmentation from MRI wrist images: Application in clinical trials in rheumatoid arthritis (RA) (2009) (1)
PATIENT EXPECTATIONS OF TREATMENT GOALS AND GOAL-SETTING PRACTICES IN RHEUMATOID ARTHRITIS IN THE UNITED KINGDOM (2012) (1)
Fine-Tuning the Treatment of Psoriatic Arthritis: Focus on the IL-23 Pathway (2019) (1)
THU0102 PATIENT DISEASE TRAJECTORIES IN BARICITINIB-TREATED PATIENTS WITH RHEUMATOID ARTHRITIS AND INADEQUATE RESPONSE TO METHOTREXATE (2019) (1)
Etanercept plus sulfasalazine: added value in rheumatoid arthritis? (2007) (1)
TNF[alpha] directly regulates in vivo corticosteroid metabolism in inflammatory arthritis (2013) (1)
BHPR - audit/service delivery 93. Taking Care of the Foot Health of Rheumatology Patients: Where Do We Stand Now? (2011) (1)
SUBCUTANEOUS GOLIMUMAB SUSTAINS EFFECTS OF INTRAVENOUS GOLIMUMAB IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS: RESULTS OF THE GO-LIVE LONG TERM EXTENSION (2011) (1)
BHPR research: qualitative1. Complex reasoning determines patients’ perception of outcome following foot surgery in rheumatoid arhtritis (2012) (1)
SAT0155 WHOLE BLOOD TRANSCRIPTIONAL CHANGES FOLLOWING SELECTIVE INHIBITION OF JANUS KINASE 1 (JAK1) BY FILGOTINIB IN MTX-NAÏVE ADULTS WITH MODERATELY-TO-SEVERELY ACTIVE RHEUMATOID ARTHRITIS (RA) (FINCH3) (2020) (1)
Articular ultrasonography in rheumatoid arthritis (2009) (1)
Sirukumab and adalimumab reduce power Doppler ultrasound signal in patients with rheumatoid arthritis by 4 weeks in a phase III trial (2019) (1)
O07 Randomised, open labelled clinical trial to investigate synovial mechanisms determining response: resistance to rituximab versus tocilizumab in RA patients failing TNF inhibitor therapy (2020) (1)
The Opportunities and Challenges of Telemedicine in the Management of People With Rheumatoid Arthritis (2022) (1)
Synovial Lymphocytic Aggregates Associate with Highly Active RA and Predict Erosive Disease at 12 Months: Results from the Pathobiology of Early Arthritis Cohort (2015) (1)
High unmet need for arthritis pain management among EU and US rheumatoid arthritis patients despite effective therapies (2008) (1)
Evolving the comprehensive management of rheumatoid arthritis: identification of unmet needs and development of practical and educational tools. (2020) (1)
SYSTEMATIC LITERATURE REVIEW OF TREATMENTS IN UNDIFFERENTIATED PERIPHERAL INFLAMMATORY ARTHRITIS (2010) (1)
24-WEEK RESULTS OF A BLINDED PHASE IIB DOSE-RANGING STUDY OF BARICITINIB, AN ORAL JAK1/JAK2 INHIBITOR, IN COMBINATION WITH TRADITIONAL DMARDS IN PATIENTS WITH RHEUMATOID ARTHRITIS (2013) (1)
O02. FILGOTINIB, AN ORAL JAK1 SELECTIVE INHIBITOR WITH A RAPID ONSET OF ACTION: RESULTS FROM THE DARWIN 1 STUDY IN METHOTREXATE INADEQUATE RESPONSE RHEUMATOID ARTHRITIS PATIENTS (2017) (1)
THU0194 SELECTIVE INHIBITION OF JANUS KINASE 1 (JAK1) BY FILGOTINIB MODULATES THE DISEASE-ASSOCIATED WHOLE BLOOD TRANSCRIPTIONAL PROFILE OF PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS (2019) (1)
Efficacy and Safety of Switching from Adalimumab to Baricitinib: Phase 3 Data in Patients with Rheumatoid Arthritis (2016) (1)
POS0660 CONCOMITANT USE OF STATINS IN FILGOTINIB-TREATED PATIENTS WITH RHEUMATOID ARTHRITIS (2021) (1)
131. Utility of Ultrasound in the Nuffield Orthopaedic Centre Emergency Rheumatology Clinic: Survey of Clinical Effectiveness (2014) (1)
Oral abstracts 3: RA Treatment and outcomesO13. Validation of jadas in all subtypes of juvenile idiopathic arthritis in a clinical setting (2012) (1)
Quality of Care in Rheumatoid Disease from the Clinician Perspective: A Modified Delphi Panel Approach (2018) (1)
TREATMENT OF RHEUMATOID-ARTHRITIS WITH ANTIBODY TO TNF-ALPHA DECREASES EXPRESSION AND SHEDDING OF E-SELECTIN (1995) (1)
COUNSELLING PATIENTS PRIOR TO STARTING ANTI-TNF THERAPY: A ROLE FOR A PATIENT EDUCATION GROUP (2011) (1)
SB4 in the Era of Biosimilars: Clinical Data and Real-World Experience (2019) (1)
057 Comparison of Biologic Disease-Modifying Anti-Rheumatic Drug Rheumatoid Arthritis Treatment Dynamics Across Five European Union Countries (2016) (1)
SYNOVIAL LYMPHOCYTIC AGGREGATES ASSOCIATE WITH HIGHLY ACTIVE RA AND PREDICT EROSIVE DISEASE PROGRESSION AT 12 MONTHS: RESULTS FROM THE PATHOBIOLOGY OF EARLY ARTHRITIS COHORT (2016) (1)
Ultrasonographic and radiographic evidence of attenuated joint destruction in early RA patients treated with infliximab (2003) (1)
The Role of TNFα in the Pathogenesis of Rheumatoid Synovitis (1999) (1)
FRI0462 UNDERSTANDING MEDIATORS OF PAIN REDUCTION IN PSORIATIC ARTHRITIS PATIENTS TREATED WITH TOFACITINIB: ROLE OF INFLAMMATION (2019) (1)
Anti-TNF Therapy: 20 Years from Our First Therapeutic Adventure (2014) (1)
A Prospective Evaluation of the Effects of Extracorporeal Photopheresis on Important Immunological Markers in Chronic Graft Versus Host Disease. (2004) (1)
Unravelling the phenotype of cardiovascular inflammation with magnetic resonance imaging: detecting the change with anti-TNF treatment in patients with rheumatoid arthritis (2011) (1)
The need for personalized medicine in rheumatoid arthritis (2013) (1)
Muscle disorders111. The impact of fatigue in patients with idiopathic inflammatory myopathy: a mixed method study (2012) (1)
An Investigation of Translocator Protein As a Tissue and Peripheral Blood Biomarker of Inflammation in Rheumatoid Arthritis (2016) (1)
POS0512 DIFFERENCES IN TREATMENT SATISFACTION, PATIENT PREFERENCES, AND TREATMENT PATTERNS BETWEEN EUROPEAN, SOUTH AMERICAN, AND JAPANESE PATIENTS WITH SUBOPTIMALLY CONTROLLED RHEUMATOID ARTHRITIS: A SUBGROUP ANALYSIS OF THE SENSE STUDY (2021) (1)
Baricitinib Safety for Events of Special Interest in Populations at Risk: Analysis from Randomised Trial Data Across Rheumatologic and Dermatologic Indications (2023) (1)
Managing inadequate response to initial anti-TNF therapy in rheumatoid arthritis: optimising treatment outcomes (2022) (1)
Novel biomarkers of a peripheral blood interferon signature associated with drug-naïve early arthritis patients distinguish persistent from self-limiting disease course (2020) (0)
Comparison of remission induction in erosive early KA assessed by DAS28 calculated using either ESR or CRP in infliximab plus MTX combination therapy or MTX monotherapy (2005) (0)
20th anniversary of TNF inhibitors in rheumatoid arthritis (2019) (0)
P204 Effect of baricitinib on functional impairment in RA patients with moderate disease activity and an inadequate response to conventional DMARDs (2020) (0)
Et tu, Brutinib? Demise of a kinase target in rheumatoid arthritis? (2023) (0)
I7. Challenge 4: Defining Strategy for Use of Biologics (2014) (0)
Faculty Opinions recommendation of Imaging and serum analysis of immune complex formation of radiolabelled infliximab and anti-infliximab in responders and non-responders to therapy for rheumatoid arthritis. (2006) (0)
Association between radiographic progression and persistent vascular signal on power doppler imaging in early rheumatoid arthritis (2006) (0)
O41 Predisposition of RA monocytes/macrophages to a pro-inflammatory phenotype through down-regulation of mitochondrial translocator protein (2018) (0)
This is a repository copy of Use of Magnetic Resonance Imaging to Support Dose Selection in a Phase II Trial of Baricitinib Combined with Conventional Synthetic Disease-modifying Antirheumatic Drugs in Rheumatoid Arthritis (2020) (0)
Basic science235. The Translocator Protein as a Marker of Macrophage and Stromal Activation in Inflammatory Arthritis: An Initial Investigation (2017) (0)
SAT0225 Comparative effectiveness in pain and haq-di improvement for baricitinib versus adalimumab, tocilizumab, and tofacitinib monotherapies in csdmard-naÏve rheumatoid arthritis patients: a matching-adjusted indirect comparison (MAIC) (2018) (0)
BCSH/BSBMT Guideline: Organ-Specific Management and Supportive Care in Chronic Graft-versus -Host Disease (2012) (0)
Recent evidence for the achievement of remission in rheumatoid arthritis through early aggressive therapy. (2006) (0)
Relationships of dermatologic symptoms and quality of life in patients with psoriatic arthritis: analysis of two tofacitinib phase III studies (2022) (0)
THU0215 WHOLE BLOOD TRANSCRIPTIONAL CHANGES FOLLOWING SELECTIVE INHIBITION OF JANUS KINASE 1 (JAK1) BY FILGOTINIB IN ADULTS WITH MODERATELY-TO-SEVERELY ACTIVE RHEUMATOID ARTHRITIS WITH PRIOR INADEQUATE RESPONSE TO METHOTREXATE (FINCH1) (2020) (0)
SAT0152 EFFICACY OF BARICITINIB IN PATIENTS WITH MODERATE-TO-SEVERE RHEUMATOID ARTHRITIS WITH 3 YEARS OF TREATMENT: RESULTS FROM A LONG-TERM STUDY (2020) (0)
High frequency power Doppler ultrasound reveals hypervascular erosions are common in early rheumatoid arthritis (2001) (0)
Tumour necrosis factor inhibitors (2020) (0)
Baricitinib: Early Vs. delayed start in patients with Rheumatoid Arthritis (2018) (0)
UNRAVELLING THE PHENOTYPE OF CARDIOVASCULAR INFLAMMATION IN PATIENTS WITH RHEUMATOID ARTHRITIS WITH MAGNETIC RESONANCE IMAGING: THERAPEUTIC BENEFITS OF TNF INHIBITION (2011) (0)
Comparison of ultrasonographic measures of synovitis and radiographic assessment of structural damage over two years in a randomised, controlled trial of infliximab therapy in erosive early rheumatoid arthritis. (2004) (0)
JOINT DESTRUCTION IS ATTENUATED BY INFLIXIMAB IN EARLY RA PATIENTS WITH ULTRASONOGRAPHIC MARKERS OF POOR PROGNOSIS (2003) (0)
Disease activity-guided tapering of biologics in patients with inflammatory arthritis: a pragmatic, randomized, open-label, equivalence trial. (2023) (0)
Uptake of [11C]PBR28 and translocator protein specificity in Inflammatory Joint disease (2019) (0)
Chapter 42 – Autoimmunity – Rheumatoid Arthritis (2005) (0)
Pain in the joints and beyond; the challenge of rheumatoid arthritis (2023) (0)
Imaging early abnormalities: A surrogate marker? (2007) (0)
ANTI-TNF THERAPY LEADS TO AN INCREASE IN CIRCULATING TH17 CELLS IN PATIENTS WITH DIFFERENT TYPES OF INFLAMMATORY ARTHRITIS AND IS ASSOCIATED WITH ULTRASONOGRAPHIC IMPROVEMENT OF SYNOVITIS (2014) (0)
Outcomes Following Adalimumab Bio-originator to Biosimilar Switch—A Comparison Using Real-world Patient- and Physician-Reported Data in European Countries (2023) (0)
OP0350 ULTRASOUND POWER DOPPLER SEMI-QUANTITATIVE SCORING, IS IT TIME WE MOVED TO A RED PIXEL DENSITY ALGORITHMIC PROGRAM TO DETERMINE TRUE TREATMENT RESPONSE? (2019) (0)
Improved Patient-Reported Outcomes in Patients with Rheumatoid Arthritis Who Failed Adalimumab or Placebo Treatment and Were Rescued with Baricitinib (2017) (0)
Approaches to optimising access to NICE-approved biologic anti-TNFs for patients with rheumatoid arthritis with moderately active disease (2023) (0)
Increases in Serum Cholesterol with Baricitinib Treatment are Associated with Favorable Changes in Apolipoprotein Content and with Improvement in DAS28-CRP in Patients with Rheumatoid Arthritis (2015) (0)
AB0360 EFFICACY AND SAFETY OF THE PROSTAGLANDIN EP4 RECEPTOR ANTAGONIST CR6086 ADDED TO METHOTREXATE IN DMARD-NAÏVE EARLY RA PATIENTS: A PHASE 2 RANDOMIZED CONTROLLED TRIAL (2020) (0)
AB0294 Treatment modes in rheumatoid arthritis: factors influencing patient preference (2018) (0)
FRI0136 PERIPHERAL PROTEIN BIOMARKER CHANGES FOLLOWING SELECTIVE INHIBITION OF JANUS KINASE 1 (JAK1) BY FILGOTINIB IN ADULTS WITH MODERATELY-TO-SEVERELY ACTIVE RHEUMATOID ARTHRITIS WITH PRIOR INADEQUATE RESPONSE TO METHOTREXATE (FINCH1) (2020) (0)
I074 The impact of nociception and mental state on disease burden in rheumatic diseases (2019) (0)
JAK inhibitors in rheumatoid arthritis (2019) (0)
POS0646 RAPID AND CONCURRENT IMPROVEMENTS IN PATIENT-REPORTED OUTCOMES OF RHEUMATOID ARTHRITIS WITH BARICITINIB IN RA-BEAM (2021) (0)
Longterm Extension Study in Patients with Rheumatoid Arthritis Safety and Efficacy of Baricitinib Through 128 Weeks in an Open-label , (2017) (0)
The William J. Cunliffe Scientific Awards (2002) (0)
64 – Cell-Targeted Biologics and Targets: Rituximab, Abatacept, and Other Biologics (2013) (0)
P167 IgG4 related disease: response to immunosuppressive therapy: a single centre retrospective study in the United Kingdom (2021) (0)
Faculty Opinions recommendation of Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. (2006) (0)
FRI0088 Synovial pathobiology correlates with diagnostic subgroups in early inflammatory arthritis: results from the pathobiology of early arthritis cohort (PEAC) (2017) (0)
Ultrasonographic evidence of attenuated joint destruction within 18 weeks in early RA patients treated with infliximab. (2003) (0)
Basic science232. Certolizumab pegol prevents pro-inflammatory alterations in endothelial cell function (2012) (0)
AB0449 PAIN REDUCTION IN PATIENTS WITH RHEUMATOID ARTHRITIS RECEIVING TOFACITINIB MONOTHERAPY WITH OR WITHOUT PAIN MEDICATION: A POST HOC ANALYSIS OF POOLED DATA FROM PHASE 2, PHASE 3 AND PHASE 3B/4 STUDIES (2019) (0)
Basic science232. Certolizumab pegol prevents pro-inflammatory alterations in endothelial cell function (2012) (0)
inflammatory response Shedding of lymphocyte function-associated antigen (LFA)-1 in a human (2011) (0)
Carotid Endarterectomy in the Elderly: Risk Factors, Intra-Operative Haemodynamics and Short-Term Complications; A Uk Tertiary Centre Experience (2010) (0)
A LYMPHOID PATHOTYPE AT BASELINE, IN EARLY INFLAMMATORY ARTHRITIS, SIGNIFICANTLY ASSOCIATES WITH REQUIREMENT FOR BIOLOGIC THERAPY AT 12 MONTHS FOLLOW UP: RESULTS FROM THE PATHOBIOLOGY OF EARLY ARTHRITIS COHORT (2018) (0)
Efficacy of baricitinib in patients with rheumatoid arthritis with three years of treatment: Results from a long-term study (2020) (0)
Lack Of Early Clinical Response To Treatment With Baricitinib Predicts Low Probability Of Achieving Long Term DAS28-ESR Low Disease Activity Or Remission In Patients With Rheumatoid Arthritis. (2013) (0)
Upregulation of the MMP-9 gene in areas of instability in carotid artery plaques (2004) (0)
Assessment of Durability of Response in Patients with Skin Graft Versus Host Disease beyond Six Months Treatment with Extracorporeal Photopheresis: Reduction of Steroid Resistance and Evaluation of Long-Term Therapy on Survival. (2008) (0)
Between-group differences in ultrasonographic measures of synovitis and kinetics of response to oral steroids in active RA (2006) (0)
223 [11C]PBR28 Macrophage Targeted Positron Emission Tomography–Computed Tomography in Rheumatoid Arthritis: Results of a Pilot Study (2016) (0)
AB0837 ITCH AS THE MAJOR MEDIATOR OF THE EFFECT OF TOFACITINIB ON HEALTH-RELATED QUALITY OF LIFE IN PsA: A MEDIATION ANALYSIS (2020) (0)
THE PATHOBIOLOGY OF EARLY ARTHRITIS COHORT: A PRELIMINARY ANALYSIS CORRELATING HISTOMORPHOLOGY AND DISEASE ACTIVITY (2012) (0)
Chapter 64 – Cell-Targeted Biologics and Emerging Targets: Rituximab, Abatacept, and Other Biologics (2017) (0)
PPA_A_220714 119..131 (2020) (0)
O02 The JAK1-selective inhibitor filgotinib reverses the disease-associated transcriptional profile in the blood of patients with active rheumatoid arthritis (2019) (0)
PMS79 Mixed Treatment Comparison of Biologic Agents in Patients with Rheumatoid Arthritis Who Have responded Inadequately to Methotrexate Therapy in the United Kingdom (2011) (0)
AB1267 ONLINE CASE-BASED EDUCATION SIGNIFICANTLY IMPROVED RHEUMATOLOGISTS’ KNOWLEDGE AND CONFIDENCE IN MANAGING PATIENTS WITH RA (2020) (0)
P128 A subgroup analysis of the efficacy of filgotinib for patients with moderately active RA following an inadequate response to methotrexate (2021) (0)
Transfer oftypeIIcollagen-induced arthritis fromDBA/1toseverecombined immunodeficiency micecan beprevented byblockade ofMac-i (1996) (0)
Ultrasonographic and radiographic results from a two-year controlled trial of immediate or one-year-delayed addition of inflixin ongoing methotrexate therapy in patients with erosive early rheumatoid arthritis (vol 54, pg 47, 2006) (2006) (0)
SYNOVIAL LYMPHOCYTE AGGREGATES IN EARLY INFLAMMATORY ARTHRITIS: CORRELATION WITH DIAGNOSIS, DISEASE ACTIVITY AND ANTIBODY STATUS (2013) (0)
BCSH/BSBMT Guideline: Diagnosis and Management of Chronic Graft- versus-Host Disease (2012) (0)
Rheumatoid Arthritis (2020) (0)
AB1255 AGREEMENT BETWEEN PATIENT-REPORTED OUTCOME MEASURES COLLECTED VIA A SMARTPHONE APPLICATION VS A TOUCHSCREEN SOLUTION IN AN OUTPATIENT CLINIC AMONG PATIENTS WITH INFLAMMATORY ARTHRITIS: A RANDOMISED, WITHIN-PARTICIPANT TRIAL (2020) (0)
Basic science235. The Translocator Protein as a Marker of Macrophage and Stromal Activation in Inflammatory Arthritis: An Initial Investigation (2017) (0)
I44 Heberden Round (2016) (0)
CHAPTER 10G – IL-1 Inhibitors in the Treatment of Rheumatoid Arthritis (2009) (0)
University of Birmingham Patient-reported outcomes and safety in patients undergoing synovial biopsy (2018) (0)
233 Durability, maintenance and effects of dose reduction following prolonged treatment with baricitinib (2018) (0)
076 Assessment of pain improvement in rheumatoid arthritis patients treated with baricitinib, who were inadequate responders to methotrexate and tumor necrosis factor inhibitors (2019) (0)
024 The mitochondrial translocator protein single nucleotide polymorphism rs6971 may influence pain and fatigue in rheumatoid arthritis: results of a preliminary study (2019) (0)
Rheumatoid arthritis 1 (2020) (0)
Treatment modes in Rheumatoid Arthritis: Moving toward shared decision-making (2018) (0)
074 Summary of indirect comparison to evaluate efficacy of baricitinib with targeted synthetic and biologic disease anti-rheumatic drugs in patients with rheumatoid arthritis (2019) (0)
I23. The Place of Biosimilars in Clinical Practice (2014) (0)
THE CLINICAL PHENOTYPE OF INFLAMMATORY ARTHRITIS CORRELATES WITH SYNOVIAL IMMUNE CELL INFILTRATION: RESULTS FROM THE PATHOBIOLOGY OF EARLY ARTHRITIS COHORT (2018) (0)
THU0100 In early inflammatory arthritis a lymphoid pathotype signficantly associates with requirement for biologic therapy at 12 months follow up: results from the pathobiology of early arthritis cohort (PEAC) (2017) (0)
Improving patient outcomes in rheumatoid arthritis - focus on biologic therapies (2013) (0)
PMS71 INDIRECT TREATMENT COMPARISON TO COMPARE EFFICACY IN HEALTH ASSESSMENT QUESTIONNAIRE (HAQ) SCORE FOR BIOLOGIC AGENTS WITH METHOTREXATE IN PATIENTS WITH RHEUMATOID ARTHRITIS AND ACTIVE DISEASE DESPITE METHOTREXATE THERAPY (2010) (0)
Pathogenic Th17 signatures in peripheral blood and faecal cytokines of ankylosing spondylitis. (2019) (0)
Preface: Future trends in the field of spondyloarthritis. (2017) (0)
AB0287 BENEFITS OF PAIN RELIEF ON FATIGUE, FUNCTION, AND QUALITY OF LIFE WHEN JOINT INFLAMMATION IS CONTROLLED IN PATIENTS WITH RA (2019) (0)
THU0216 PERIPHERAL PROTEIN BIOMARKER CHANGES FOLLOWING SELECTIVE INHIBITION OF JANUS KINASE 1 (JAK1) BY FILGOTINIB IN METHOTREXATE NAÏVE ADULTS WITH MODERATELY-TO-SEVERELY ACTIVE RHEUMATOID ARTHRITIS (FINCH3) (2020) (0)
Resource Molecular Portraits of Ear ly Rheumatoid Arthritis Identify Clinical and Treatment Response Phenotypes Graphical (2019) (0)
P215 Filgotinib, a janus kinase 1 selective inhibitor, modulates disease-associated cytokines in patients with active RA (2020) (0)
Utility of [11C]PBR28 PET in the imaging of inflammatory arthritis (2017) (0)
The use of JAK inhibitors in the treatment of rheumatoid arthritis (2020) (0)
Central sensitisation: causes, therapies, and terminology (2021) (0)
Management in Rheumatoid Arthritis Patient Expectations and Perceptions of Goal-setting Strategies for Disease (2015) (0)
THE ROLE OF AMINO-PROPEPTIDE OF TYPE III COLLAGEN AND HYALURONIC ACID AS BIOMARKERS FOR SYNOVIAL VOLUME IN PATIENTS WITH RHEUMATOID ARTHRITIS (2012) (0)
Faculty Opinions recommendation of Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. (2006) (0)
POS0649 BARICITINIB PROVIDES GREATER IMPROVEMENTS IN PATIENT-REPORTED OUTCOMES ACROSS ALL DISEASE ACTIVITY LEVELS COMPARED TO PLACEBO AND ADALIMUMAB IN RHEUMATOID ARTHRITIS (2021) (0)
Quantitative power Doppler and greyscale ultrasound demonstrate an association between vascularity and erosions in early rheumatoid arthritis (2001) (0)
P107 Long-term efficacy of baricitinib in patients with rheumatoid arthritis with inadequate response to bDMARDs: results from RA-BEYOND up to 6.9-years of treatment (2023) (0)
Identifying and Quantifying the Role of Inflammation in Pain Reduction for Patients With Psoriatic Arthritis Treated With Tofacitinib: A Mediation Analysis (2022) (0)
Treat-to-target in rheumatoid arthritis: a real-world study of the application and impact of treat-to-target within the wider context of patient management, patient centricity and advanced therapy use in Europe (2022) (0)
Real-life drug persistence in patients with rheumatic diseases treated with CT-P13: a prospective observational cohort study (PERSIST) (2021) (0)
POS0446 FILGOTINIB-TREATED RHEUMATOID ARTHRITIS PATIENTS WITH HIGH BASELINE NEUTROPHIL-TO-LYMPHOCYTE RATIO SHOW BETTER CLINICAL RESPONSE RATES AND PATIENT-REPORTED OUTCOMES (2021) (0)
POS0305 PHYSICIAN AND PATIENT ATTITUDES TOWARDS TREAT-TO-TARGET, ITS IMPLEMENTATION AND STATED TREATMENT GOALS IN PATIENTS WITH RHEUMATOID ARTHRITIS IN A REAL-WORLD SETTING ACROSS EUROPE (2021) (0)
AB1045 Macrophage targeted positron emission tomography (PET) for the imaging of inflammatory arthritis; an in vivo and in vitro investigation of translocator protein (TSPO) tracer uptake (2017) (0)
P127 Baricitinib Efficacy in Moderate Rheumatoid Arthritis - A Post-hoc Analysis from two Phase III Trials (2023) (0)
SAT0231 Effects of the jak1-selective inhibitor filgotinib on gene expression profile in blood of patients with active rheumatoid arthritis (2018) (0)
OP0100 MOLECULAR PROFILING OF PERIPHERAL IMMUNE CELL SUBSETS IN PATIENTS WITH RHEUMATOID ARTHRITIS (2020) (0)
Ethical Issues in a TwiCs study in early PsA (2017) (0)
OP0120 BASELINE CELLULAR AND MOLECULAR CHARACTERISTICS OF SYNOVIAL TISSUE AND RELATION WITH TNFI RESPONSE. RESULTS FROM THE PATHOBIOLOGY OF THE EARLY ARTHRITIS COHORT (PEAC) (2019) (0)
SIGNIFICANT CHANGES IN SONOGRAPHIC MEASURES OF JOINT VASCULARITY AND SERUM VEGF IN EARLY RA PATIENTS ON INFLIXIMAB BY 18 WEEKS OF THERAPY (2002) (0)
Risk of harm in synthetic and biological intervention trials in patients with inflammatory arthritis: protocol for a metaepidemiological study focusing on contextual factors (2021) (0)
P236 Baricitinib provides better pain relief across all disease activity levels compared with placebo and adalimumab in RA (2020) (0)
Biosimilars: An Opportunity to Update the Product Information of Biological Drugs Regarding their Immunogenicity (2019) (0)
THU0088 Monocyte downregulation of mitochondrial translocator protein may be a contributory mechanism to inflammation in ra (2018) (0)
FRI0133 FILGOTINIB, A SELECTIVE JANUS KINASE 1 (JAK1) INHIBITOR, MODULATES DISEASE-ASSOCIATED CYTOKINES IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS (2019) (0)
Cell-Targeted Biologics and Emerging Targets (2017) (0)
Abnormalities Requiring Immediate Correction After Intraoperative Control During Carotid Reconstruction (2008) (0)
OP0240 Synovial Lymphocytic Aggregates Associate with Highly Active RA and Predict Erosive Disease Progression at 12 Months: Results from The Pathobiology of Early Arthritis Cohort (2016) (0)
Rituximab versus tocilizumab and B-cell status in TNF-alpha inadequate-responder rheumatoid arthritis patients: the R4-RA RCT (2022) (0)
Impact of initial therapy with upadacitinib or adalimumab on achievement of 48-week treatment goals in patients with rheumatoid arthritis: post hoc analysis of SELECT-COMPARE (2022) (0)
Comparative Histologic and Molecular Analysis of Synovial Tissue in Early Treatment-Naive Psoriatic and Rheumatoid Arthritis (2018) (0)
Patient Disease Trajectories in Rheumatoid Arthritis Patients Treated with Baricitinib 4-mg in Four Phase 3 Clinical Studies (2023) (0)
D DIMER assay—its use in the investigation of DVT (1997) (0)
A5.10 Increases in serum cholesterol with baricitinib treatment are associated with favourable changes in apolipoprotein content and with improvement in DAS28-CRP in patients with rheumatoid arthritis (2015) (0)
THE LONG-TERM COMPLICATIONS OF NON-FATAL RHEUMATOID ARTHRITIS (2018) (0)
226 Summary of baricitinib effect on patient-reported outcomes (PROs) in methotrexate-inadequate responder patient population (2018) (0)
Median time to pain improvement in patients with psoriatic arthritis treated with tofacitinib (2018) (0)
Special Lectures on the Pathogenesis and the Pathogenesis-based Treatment of Rheumatoid Arthritis. Insights into the pathogenesis of rheumatoid arthritis from application of anti-TNF therapy. (2000) (0)
Discordance between power Doppler and DAS28 assessment of remission induction in a randomised, placebo-controlled stud of infliximab therapy in early rheumatoid arthritis (2005) (0)
FRI0122 REAL-WORLD SAFETY DATA FROM PATIENTS WITH RHEUMATIC DISEASES TREATED WITH CT-P13, AN INFLIXIMAB BIOSIMILAR: AN INTERIM ANALYSIS FROM AN OBSERVATIONAL STUDY (2019) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Peter C. Taylor?

Peter C. Taylor is affiliated with the following schools:

Peter C. Taylor's Academic­Influence.com Rankings